The relationship between using estrogen and/or progesterone and the risk of mammary gland hyperplasia in women: a meta-analysis

Abstract

Background

As reported that the usage of estrogen and/or progesterone increases the risk of mammary gland hyperplasia (MGH) with conflicting results. Therefore, we conducted a meta-analysis to higher elucidate the relationship between hormones and MGH.

Method

PubMed, Embase, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, and Wan-fang database were searched for studies until April 28, 2021.

Results

Nine related studies were included in the present meta-analysis. We found that the usage of estrogen and/or progesterone had a significant association with increasing the risk of MGH (RR = 1.56, 95% CI: 1.13–2.15, p = .000). The subgroup results showed that the risk of MGH increased in the Mix population (RR = 1.72, CI: 1.58–1.88, p < .001) but no significant difference in the Asian population. Meanwhile, as for using estrogen plus progesterone (EPP) and postmenopausal women the risk of MGH, respectively, increased (RR = 1.74, CI: 1.22–2.47, p = .002) and (RR = 1.75, CI: 1.24–2.47, p = .001) but no significant different for using estrogen alone and premenopausal women.

Conclusions

This study findings indicated that using estrogen and/or progesterone might increase the risk of MGH in premenopausal and postmenopausal women.

摘要

背景：应用雌激素和/或孕激素对增加乳腺增生（MGH）风险的效果存在争议。因此，我们进行了荟萃分析，以进一步阐明激素与MGH之间的关系。

方法：检索截至2021年4月28日前PubMed、Embase、WEB OF SCIENCE数据库、Cochrane图书馆、中国知识资源总库和万方数据库。

结果：本荟萃分析纳入9项相关研究。研究发现雌激素和/或孕激素的应用与MGH风险的增加有显著关联（RR=1.56，95%CI:1.13-2.15，p=.000）。亚组结果显示，混合人群中MGH的风险增加（RR=1.72，CI:1.58-1.88，p<.001），但在亚洲人群中无显著差异。同时，对于使用雌孕激素联合应用（EPP）和绝经后女性，MGH的风险分别增加（RR=1.74，CI:1.22-2.47，p=.002）和（RR=1.75，CI:1.24-2.47，p=.001），但单独应用雌激素和绝经前女性没有显著差异。

结论：本研究结果表明，应用雌激素和/或孕激素可能会增加绝经前和绝经后女性发生MGH的风险。

Keywords:

• Hormone
• estrogen
• progesterone
• mammary gland hyperplasia

关键词:

• 激素
• 雌激素
• 孕激素
• 乳腺增生

Acknowledgments

We thank the teachers and students of the college of pharmacy at Dali University for their contribution.

Disclosure statement

There are no identified conflicts of interest with any of the authors.

Funding

The author(s) reported there is no funding associated with the work featured in this article.